| Literature DB >> 35492515 |
Gangireddy Sujeevan Reddy1,2, Kazi Amirul Hossain1, Jetta Sandeep Kumar1,2, B Thirupataiah1,2, Rebecca Kristina Edwin1, Varadaraj Bhat Giliyaru2, Raghu Chandrashekhar Hariharapura2, G Gautham Shenoy2, Parimal Misra1, Manojit Pal1.
Abstract
A series of novel isatin-indole derivatives has been designed as potential inhibitors of chorismate mutase (CM) that is known to be present in bacteria, fungi and higher plants but not in human. The design was supported by in silico docking studies that predicted strong interactions of these molecules with CM. The target compounds were synthesized via the one-pot coupling/cyclization method involving the reaction of an isatin based terminal alkyne with 2-iodosulfanilides under Pd-Cu catalysis. A number of isatin-indole derivatives were prepared using this method. A side product e.g. 2-indolylmethylamino benzoate ester derivative was obtained as a result of isatin ring opening (ethanolysis) of products in certain cases. Additionally, regioselective reduction of selected compounds afforded the corresponding C-3 hydroxy derivatives. All isatin-indole derivatives showed good to high inhibition of CM in vitro among which two compounds (3e and 3f) showed inhibition at nanomolar concentration. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35492515 PMCID: PMC9047634 DOI: 10.1039/c9ra09236f
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Representative isatin derivatives reported as anti-tubercular agents.
Fig. 2Design of new isatin–indole framework F based on isatin D and the known inhibitor E.
Docking of molecules into MtbCM a
| Molecules | AutoDock Vina score (kcal mol−1) |
|---|---|
|
| −9.7 |
|
| −8.8 |
|
| −9.3 |
|
| −6.9 |
|
| −7.3 |
|
| −6.2 |
E, G and D are known/reference compounds.
Fig. 3The 3D interaction diagram of (i) molecule F-1 and (ii) molecule F-3 with interface residues of chorismate mutase (PDB code: 2FP2) (the A chain is in red color, and B chain is orange color) that were prepared in Maestro visualizer (Schrödinger, LLC).
Scheme 1Coupling of isatin based alkyne 1 with 2-iodosulfanilides (2) under Pd/Cu-catalysis.
The coupling of alkyne 1 with 2-iodosulfanilide 2a under various reaction conditionsa
|
| ||||
|---|---|---|---|---|
| Entry | Catalyst | Solvent | Yield | |
| 3a | 4a | |||
| 1 | Pd(PPh3)2Cl2/CuI | EtOH | 60 | 30 |
| 2 | Pd(PPh3)2Cl2/CuI | EtOH | 25 | 0 |
| 3 | Pd(PPh3)2Cl2/CuI | EtOH | 30 | 0 |
| 4 | Pd(PPh3)2Cl2/CuI | MeOH | 50 | 35 |
| 5 | Pd(PPh3)2Cl2/CuI | tBuOH | 20 | 0 |
| 6 | Pd(PPh3)2Cl2/CuI | PEG-400 | 55 | 0 |
| 7 | Pd(PPh3)2Cl2 | EtOH | 0 | 0 |
| 8 | CuI | EtOH | 0 | 0 |
| 9 | Pd(PPh3)2Cl2/Cu(OAc)2 | EtOH | 50 | 25 |
| 10 | Cu(OAc)2 | EtOH | 0 | 0 |
| 11 | Pd(OAc)2 | EtOH | 0 | 0 |
| 12 | Pd(OAc)2/CuI | EtOH | 0 | 0 |
| 13 | 10%Pd–C/PPh3/CuI | EtOH | 0 | 0 |
Reaction conditions: all the reactions were carried out using 1 (1 mmol), 2 (1.2 mmol), a Pd-catalyst (5 mol%) and Cu-catalyst (5 mol%) in the presence of Et3N (3 mmol) in a solvent (10 mL) at 60 °C for 2–3 h.
Isolated yield.
K2CO3 was used as a base.
Cs2CO3 was used as a base.
Corresponding methyl ester was obtained.
The reaction was performed for 6–8 h.
Synthesis of isatin–indole derivatives (3) along with 2-indolylmethylamino benzoate ester derivative 4 (Scheme 1)a
| Entry | Anilides (2) | Products (3) | Products (4) |
|---|---|---|---|
| 1 |
|
|
|
| 2 |
|
|
|
| 3 |
|
|
|
| 4 |
|
|
|
| 5 |
|
|
|
| 6 |
|
|
|
| 7 |
|
|
|
| 8 |
|
|
|
| 9 |
|
|
|
| 10 |
|
|
|
| 11 |
|
| Trace |
| 12 |
|
| Trace |
| 13 |
|
| Trace |
Figure in the bracket indicates isolated % yield.
MeOH was used as a solvent in place of EtOH.
Scheme 2Regioselective reduction of compound 3d, 3f, 3h and 3i.
Fig. 4Partial 1H and 13C NMR data of compound 3, 4 and 5.
Scheme 3The plausible reaction mechanism for the formation compound 3 under Pd/Cu-catalysis.
Scheme 4The proposed reaction mechanism for the formation of compound 4.
In vitro evaluation of isatin–indole derivatives (3) against CM
| Compounds | % Inhibition @ 30 μM | Compounds | % Inhibition @ 30 μM |
|---|---|---|---|
| 3a | 66.83 | 4a | 4.54 |
| 3b | 67.53 | 4b | 9.59 |
| 3c | 71.36 | 4c | 1.38 |
| 3d | 67.67 | 4e | 14.18 |
| 3e | 73.43 | 4f | 15.34 |
| 3f | 74.20 | 4h | 26.29 |
| 3g | 47.93 | 4j | 14.12 |
| 3h | 70.28 | 5a | 18.65 |
| 3i | 71.61 | 5b | 10.26 |
| 3j | 72.92 | 5c | 5.93 |
| 3k | 67.30 | ||
| Compound G | 56.97 |
Data represent the mean values of three independent determinations.
Fig. 5Summary of SAR for CM inhibitory activities of compound 3.
Concentration dependent study of compound 3e and 3f against CM
| Compound concentration | % Inhibition | |
|---|---|---|
| 3e | 3f | |
| 30 μM | 73.43 | 74.20 |
| 10 μM | 61.32 | 68.91 |
| 3 μM | 55.18 | 54.23 |
| 1 μM | 51.87 | 57.96 |
| 300 nM | 52.07 | 55.40 |
| 100 nM | 50.46 | 54.27 |
| 30 nM | 42.04 | 37.98 |
| 10 nM | 31.70 | 24.93 |
Data represent the mean values of three independent determinations.
Computational ADME prediction of 3e, 3f and G
| Properties | Molecules | ||
|---|---|---|---|
| 3e | 3f | G | |
|
| |||
| Molecular weight (g mol−1) | 388.82 | 416.45 | 425.41 |
| Consensus log | 2.68 | 3.28 | 0.90 |
| log | −4.25 (moderately soluble) | −5.03 (moderately soluble) | −3.63 (soluble) |
|
| |||
| GI | High | High | Low |
| BBB | No | No | No |
| P-gp | No | No | Yes |
|
| |||
| Lipinski rule | No violation | No violation | No violation |
| Veber rule | No violation | No violation | 1 Violation (TPSA >140; |
| Bioavailability score | 0.55 | 0.55 | 0.11 |
log P: lipophilicity.
log S (ESOL): water solubility, calculated by ESOL method which quantitative structure–property relationship (QSPR) based model.
GI: gastrointestinal.
BBB: blood brain barrier.
P-gp: permeability glycoprotein.